MINNEAPOLIS, Feb. 4 /PRNewswire-FirstCall/ -- Uroplasty, Inc. announced today that it will release financial results for the third quarter of fiscal 2008 ended December 31, 2007, before the market opens on Monday, February 11, 2008. The Company will host a conference call to discuss these results on Monday, February 11, 2008 at 10:00 a.m. Central Time. David Kaysen, President and Chief Executive Officer, and Medi Jiwani, Vice President, Chief Financial Officer and Treasurer, will host the call. Individuals wishing to participate in the conference call should dial 800-240-5318 (domestic) or 303-262-2140 (international). An audio replay will be available for 7 days following the call at 800-405-2236 (domestic) or 303-590-3000 (international), with the passcode 11108161#.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent PC(R) system, which we believe is the only FDA-approved non-surgical neurostimulation therapy for the treatment of overactive bladder symptoms (OAB). We also offer Macroplastique(R) Implants, a bulking agent for the treatment of urinary incontinence. Please visit Uroplasty, Inc. at http://www.uroplasty.com.
CONTACT: David Kaysen, President and CEO, or Medi Jiwani, Vice President,
CFO, and Treasurer, both of Uroplasty, Inc., +1-952-426-6140; or Investors,
Matthew Selinger, +1-415-896-6817, or Media, Chris Gale, +1-646-201-5445,
both of EVC Group for Uroplasty, Inc.
Web site: http://www.uroplasty.com/
